NHI.no
Annonse
Informasjon, tilstand

Cystisk fibrose

Cystisk fibrose er en arvelig sykdom med forstyrrelser i kjertelfunksjonen i flere organ. Det er særlig symptomer fra lungene og magetarmkanalen som dominerer sykdomsbildet.

Fra 2012 testes alle norske barn for cystisk fibrose i forbindelse med nyfødtscreening. (Illustrasjonsfoto: Colourbox)

Sist oppdatert:

7. des. 2023

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Cystisk fibrose . Referanselisten for dette dokumentet vises nedenfor

  1. Elborn JS. Cystic fibrosis. Lancet 2016; 388:2519. PubMed
  2. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195-2211. PMID: 34090606.
  3. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606. PubMed
  4. Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125(suppl): 1-39.
  5. Katkin JP. Cystic fibrosis: Clinical mamnnifestations and diagnosis. UpToDate, last updated Aug 20, 2020. UpToDate
  6. Dorlöchter L, Røksund OD, Fluge G, Rosendahl K. Høyoppløsningscomputertomografi av lungene ved cystisk fibrose. Tidsskr Nor Lægeforen 2002; 122: 1549-51. PubMed
  7. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 2006; 149: 362-6. PubMed
  8. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-35. PubMed
  9. Desax MC, Ammann RA, Hammer J, et al. Nanoduct(R) sweat testing for rapid diagnosis in newborns, infants and children with cystic fibrosis. Eur J Pediatr 2007, April 14. Epub ahead of print.
  10. Murphy MP, Caraher E. Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms. Drugs R D. 2016 Mar;16(1):1-17. pmid: 26747453. PubMed
  11. Ratjen F, Davis SD, Stanojevic S, et al. Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019 Sep;7(9):802-9. PubMed
  12. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69. PubMed
  13. Radtke T, Nevitt SJ, Hebestreit H, Kriemler S. Physical exercise training for cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 11. Art. No.: CD002768. DOI: 10.1002/14651858.CD002768.pub4. DOI
  14. Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin K supplementation for cystic fibrosis. Cochrane Database Syst Rev. 2015 Jan 18;1:CD008482. doi: 10.1002/14651858.CD008482.pub4. DOI
  15. Lai HJ. Classification of nutritional status in cystic fibrosis. Curr Opin Pulm Med 2006; 12: 422-7. PubMed
  16. Burton CM, Milman N, Carlsen J, Arendrup H, Eliasen K, Andersen CB, et al. The Copenhagen National Lung Transplant Group: survival after single lung, double lung, and heart-lung transplantation. J Heart Lung Transplant 2005; 24: 1834-43. PubMed
  17. Ciofu O, Lykkesfeldt J. Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2014 ;8:CD007020. doi: 10.1002/14651858.CD007020.pub3. The Cochrane Library
  18. Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693. Published 2023 Feb 8. PMID: 36755044 PubMed
  19. Kapouni N, Moustaki M, Douros K, Loukou I. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Children (Basel). 2023;10(3):554. Published 2023 Mar 15. PMID: 36980112. PubMed
  20. Patel S, Sinha IP, Dwan K, Echevarria C, Schechter M, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews 2015, Issue 3. Art. No.: CD009841. DOI: 10.1002/14651858.CD009841.pub2 DOI
  21. Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015. doi:10.1056/NEJMoa1409547 DOI
  22. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019; 381: 1809-19 2019. doi: 10.1056/NEJMoa1908639 DOI
  23. Heijerman HGM, KcKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet 2019. pmid: 31679946 PubMed
  24. Lee TWR, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database of Systematic Reviews 2013; 11: CD005599. doi:10.1002/14651858.CD005599.pub4 DOI
  25. Alton EWFW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phasse 2b trial. Lancet Respir Med 2015. doi:10.1016/S2213-2600(15)00245-3 DOI
  26. Flume PA, O'Sullivan BP, Robinson KA, et al, and the Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69. PubMed
  27. Balaguer A, González de Dios J. Home versus hospital intravenous antibiotic therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD001917. DOI: 10.1002/14651858.CD001917.pub4. DOI
  28. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev. 2014 ;10:CD001915. PMID: 25300165. PubMed
  29. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013 Apr 1;187(7):680-9. PubMed
  30. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-40. PubMed
  31. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009; 15: CD001506. Cochrane (DOI)
  32. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 362-9. PubMed
  33. Accurso FJ, Schaberg A, Durham T, et al. Pulmonary function decline over one year in cystic fibrosis patients: An exploratory analysis of the phase 3 (TIGER-1) trial of aerosolized denufosol. Am J Resp Crit Care 2011.
  34. Liang J, Higgins T, Ishman SL, et al. Medical management of chronic rhinosinusitis in cystic fibrosis: a systematic review. Laryngoscope. 2014 ;124(6):1308-13. PMID: 24338982 PubMed
  35. McArdle JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med 2007; 28: 347-60. PubMed
  36. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019 Sep 9;(9):CD001505. Cochrane (DOI)
  37. Warnock L, Gates A. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD001401. DOI: 10.1002/14651858.CD001401.pub3. DOI
  38. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005; 171: 1053-9. PubMed
  39. Liou TG, Adler FR, Cox DR, and Cahill BC. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007; 357: 2143-52. PubMed
  40. Allen J, Visner G. Lung transplantation in cystic fibrosis - primum non nocere?. N Engl J Med 2007; 357: 2186-8. PubMed
  41. Conway SP, Morton A, Wolfe S. Enteral tube feeding for cystic fibrosis. The Cochrane Collaboration, 12 May 2010. CD001198.pub2. Cochrane (DOI)
  42. Sarles J, Berthezene P, Le Louarn C, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005; 147: 302-5. PubMed
  43. Hnin K, Nguyen C, Carson KV, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database of Syst Rev 2015, Issue 8. Art. No.: CD001392. DOI: 10.1002/14651858.CD001392.pub3. DOI
  44. Johansen HK, Gotzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013; 6: CD001399. doi:10.1002/14651858.CD001399.pub3 DOI
  45. McMullen AH, Pasta DJ, Frederick PD, et al. Impact of pregnancy on women with cystic fibrosis. Chest 2006; 129: 706-11. PubMed
  46. Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med 2006; 12: 453-8. PubMed
  47. George PM, Banya W, Pareek N, et al. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ 2011; 342: d1008. BMJ (DOI)
  48. MacKenzie T, Gifford AH, Sabadosa KH, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: Survival analysis of the cystic fibrosis foundation patient registry . Ann Intern Med 2014; 161: 233-41. doi:10.7326/M13-0636 DOI
Annonse
Annonse